Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2565 of 9043 results

  1. Pulsed Field Ablation for Atrial Fibrillation

    Awaiting development Reference number: GID-HTG10866 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  2. Ianalumab for treating active Sjogren's syndrome ID6634

    In development Reference number: GID-TA11836 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Admilparant for treating idiopathic pulmonary fibrosis [TSID12393]

    Awaiting development Reference number: GID-TA12004 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment

    Awaiting development Reference number: GID-HTG10389 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  5. DOASENSE DOAC dipstick product for the detection of direct oral anti-coagulants

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  6. Polyendocrine Metabolic Ovarian Syndrome (PMOS)

    In development Reference number: GID-NG10436 Expected publication date:  09 December 2026

    NICE guideline
    In development

  7. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  11 September 2026

    NICE guideline
    In development

  8. Woundexpress MT602 (MIB261)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  9. Dupilumab for treating chronic spontaneous urticaria inadequately controlled by H1 antihistamines in children 2 to 11 years [TSID12421]

    Awaiting development Reference number: GID-TA12472 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Ruxuplam for treating Huntington's disease [TSID12429]

    Awaiting development Reference number: GID-TA12476 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Tinnitus

    Awaiting development Reference number: GID-QS10091 Expected publication date: TBC

    Quality standard
    Awaiting development

  14. Kodex EPD system MT575 (MIB260)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date:  10 June 2027

    Technology appraisal guidance
    Awaiting development